Galmed Pharmaceuticals (GLMD) Total Current Liabilities (2013 - 2025)

Galmed Pharmaceuticals' Total Current Liabilities history runs 13 years deep, the most recent figure standing at $2.8 million for Q4 2025.

• In Q4 2025, Total Current Liabilities rose 30.92% year-over-year to $2.8 million; the TTM figure through Dec 2025 stood at $2.8 million (up 30.92% YoY), while the FY2025 annual figure was $2.8 million, up 30.92% from the prior year.
• Total Current Liabilities was $2.8 million for Q4 2025 at Galmed Pharmaceuticals, up from $2.5 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $7.1 million in Q1 2021 to a low of $184000.0 in Q1 2023.
• Historically, Total Current Liabilities has averaged $3.4 million across 5 years, with a median of $2.7 million in 2022.
• The sharpest annual moves came in 2021 and 2024: Total Current Liabilities sank 99.93% in 2021, then jumped 859.24% in 2024.
• A 5-year view of Total Current Liabilities shows it stood at $5.9 million in 2021, then tumbled by 47.37% to $3.1 million in 2022, then decreased by 11.12% to $2.8 million in 2023, then retreated by 20.98% to $2.2 million in 2024, then surged by 30.92% to $2.8 million in 2025.
• The last three Total Current Liabilities figures came in at $2.8 million (Q4 2025), $2.5 million (Q3 2025), and $2.4 million (Q2 2025), per Business Quant data.